My iggy on Chrome works fine. Still suffering with no iggy on IE.
"Who will choose to pay two to three times what it costs otherwise?"
Uhhhhh, let's see. How about the $1 billion market of Lovaza?
You would think they would get the hint that this is one of the stupidest arguments ever.
neiman, still scratching your head? I saw the article on SNTS news where I am invested. I guess you like the constant Rajing you get here. Fine, enjoy.
Glad to see SNTS and SPPI compared. I left SPPI for SNTS several years ago. Nice 5 bagger there. SPPI was up to $17 or so at some point. I wonder if some longs cashed out. I see a few of the diehards still here and are apparently going down with the ship.
I saw the similarity of the companies back then with one mighty exception. There is no Raj at SNTS. No greedy CEO who has no clue how to execute. No product built on only the scaricity of a generic with no better benefit itself. Not too late for the SNTS train people.
Let the over the counter guys keep buying there. How about all those Lovaza users (to the tune of 1 bill annually) choose Lovaza instead of your over the counter fish oil? Vascepa will target them. Why does this stupid "question" keep coming up? Best you can do?
Cro, one small detail, earnings will be before May 18 and I doubt it will be a quiet period either way.
I say let OMTH hit the roof. It would only make sense that AMRN with a superior ALREADY APPROVED AND ON THE MARKET drug would be celestial in comparison.
Wow AMRN not profitable through 2014.
Consesus of who? Jethro and Butch Motley down at the local saloon?
I'm gonna cut and paste that tidbit for future "truth adjustment" at the Fool.